JPMorgan Chase & Co. Issues Positive Forecast for Illumina (NASDAQ:ILMN) Stock Price

Illumina (NASDAQ:ILMN) had its price target raised by JPMorgan Chase & Co. from $120.00 to $125.00 in a research note issued to investors on Friday,Benzinga reports. The brokerage currently has a neutral rating on the life sciences company’s stock.

ILMN has been the subject of several other reports. Stifel Nicolaus upped their price target on Illumina from $135.00 to $155.00 and gave the stock a “buy” rating in a research note on Tuesday, January 20th. Piper Sandler lowered their target price on shares of Illumina from $195.00 to $170.00 and set an “overweight” rating on the stock in a report on Monday, February 9th. Guggenheim upped their target price on shares of Illumina from $144.00 to $170.00 and gave the stock a “buy” rating in a research report on Monday, January 26th. Barclays raised their target price on shares of Illumina from $110.00 to $122.00 and gave the company an “underweight” rating in a research note on Friday. Finally, Robert W. Baird set a $137.00 price target on shares of Illumina in a research note on Friday, February 6th. Six investment analysts have rated the stock with a Buy rating, ten have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $130.13.

Illumina Price Performance

NASDAQ:ILMN traded up $9.04 on Friday, reaching $135.78. 2,773,595 shares of the company’s stock traded hands, compared to its average volume of 1,369,203. The stock has a 50-day simple moving average of $125.68 and a 200-day simple moving average of $126.43. Illumina has a 12 month low of $73.86 and a 12 month high of $155.53. The firm has a market cap of $20.63 billion, a PE ratio of 24.91, a P/E/G ratio of 2.43 and a beta of 1.42. The company has a quick ratio of 1.72, a current ratio of 2.08 and a debt-to-equity ratio of 0.55.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Thursday, April 30th. The life sciences company reported $1.15 earnings per share for the quarter, topping analysts’ consensus estimates of $1.05 by $0.10. Illumina had a return on equity of 31.71% and a net margin of 19.42%.The firm had revenue of $1.09 billion during the quarter, compared to analyst estimates of $1.07 billion. During the same quarter in the prior year, the company posted $0.97 earnings per share. The business’s quarterly revenue was up 4.8% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. Equities research analysts forecast that Illumina will post 5.12 earnings per share for the current year.

Insider Activity

In other news, SVP Patricia Leckman sold 2,370 shares of the stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $116.18, for a total transaction of $275,346.60. Following the completion of the transaction, the senior vice president directly owned 16,321 shares in the company, valued at approximately $1,896,173.78. This represents a 12.68% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 2.90% of the stock is owned by company insiders.

Hedge Funds Weigh In On Illumina

Institutional investors have recently bought and sold shares of the business. Elyxium Wealth LLC bought a new stake in shares of Illumina in the 4th quarter worth about $25,000. Board of the Pension Protection Fund purchased a new stake in shares of Illumina during the 4th quarter valued at about $26,000. Creative Capital Management Investments LLC lifted its holdings in shares of Illumina by 160.0% in the 4th quarter. Creative Capital Management Investments LLC now owns 195 shares of the life sciences company’s stock valued at $26,000 after acquiring an additional 120 shares during the last quarter. TD Waterhouse Canada Inc. purchased a new position in Illumina in the fourth quarter worth about $26,000. Finally, Laurel Wealth Advisors LLC purchased a new position in Illumina in the fourth quarter worth about $26,000. Institutional investors own 89.42% of the company’s stock.

Key Stories Impacting Illumina

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Q1 beat on both EPS and revenue, with non‑GAAP EPS $1.15 vs. $1.05 consensus and revenue $1.09B (up 4.8% y/y); management raised FY‑2026 EPS guidance to $5.15–$5.30 and updated revenue targets — this underpins the stock strength. Illumina Reports Financial Results for First Quarter of Fiscal Year 2026
• Positive Sentiment: Management cited surging NovaSeq X demand and growth in clinical sequencing as a primary driver of revenue momentum — a product‑driven acceleration that supports durable top‑line growth. ILMN Q1 deep dive: Clinical sequencing fuels growth as NovaSeq X demand surges
• Positive Sentiment: Board authorized an additional $1.5B in share repurchases, expanding buybacks alongside better margins — a capital‑return boost that can support near‑term EPS and investor sentiment. Illumina lifts 2026 outlook and expands share buybacks
• Neutral Sentiment: Analysts are updating models: JPMorgan raised its price target to $125 but kept a “neutral” rating, reflecting mixed views on near‑term upside despite operational improvements. Analyst Price Target Update
• Negative Sentiment: Even with the PT bump, the $125 target implies a mid‑single‑digit to low‑double‑digit downside from current levels — a reminder that some analysts still see limited valuation upside and room for multiple compression. Analyst Price Target Update

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.